CatalystMarker
← board

ORGO

Organogenesisdistress 0/10 · well-funded / low risk
$2.44-1%today-63% from 52w high
organogenesis.com854 employeesCanton, MADrug Manufacturers - Specialty & Generic
Pain 1
Lead: knee osteoarthritis
Revenue
$37M
Liquidity
$91M
Runway
Shares 1y
+1%

Price & events

-39.0% over 6M
$2.24$3.24$4.23Jan 26Apr 26Jul 2618.5Mrating: Truist Securities: Hold (2026-05-28)rating: BTIG: Buy (2026-03-26)rating: BTIG: Buy (2026-02-27)
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
-8.6%
1W
+0.5%
1M
+4.8%
3M
-37.7%
6M
-51.0%
1Y
-23.0%
2Y
-83.7%
5Y
-68.9%
All

Overview

Market Cap
$314.13M
Volume
40.84K
52 Week Range
$2.24 – $6.54
Total Shares
128.67M
Float Shares
57.38M
Short %
16.87%
% Held by Insiders
47.46%
% Held by Institutions
49.56%
RVOL
0.05x
Beta
1.33

Pipeline stages · 1 programs

Amniotic Suspension Allograft, Placebo
Preclin
Ph1
Ph2
Ph3
Filed
PDUFA
Approved

Pipeline · 1 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2025-08-15
Phase 3Amniotic Suspension Allograft, PlaceboKnee Osteoarthritis594completed

Catalyst news & presentations · 2

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 128,674,548 · 0 offerings/1y · 0 PIPEs
  • 2025-12-298-Kmaterial_agreement
  • 2025-08-078-Kmaterial_agreement
  • 2024-12-23424B3offering
  • 2024-12-20EFFECTshelf_effective
  • 2024-12-19S-3shelf_registration
  • 2024-12-028-Kmaterial_agreement
  • 2024-11-228-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

hold · target $3 (+23% upside) · 1 analysts
  • 2026-05-28Truist SecuritiesHold
  • 2026-03-26BTIGBuy
  • 2026-02-27BTIGBuy
  • 2025-12-26BTIGBuy
  • 2025-12-15BTIGBuy
  • 2025-11-20BTIGBuy

Competitors — knee osteoarthritis

  • ENLVEnlivex Ltd.$1.0B · D7
  • NONOFNOVO NORDISK A S · D2

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.